Top AI Companies in San Diego, CA (116)

Strong Revenue Growth: Global revenue increased to $60.2B in FY2026, with growth accelerating versus the prior year and all major service lines expanding. Asia Pacific and the Americas contributed most, though expansion was not uniform across regions.

Innovation-Driven Growth: Significant, multi‑billion investments are scaling AI and technology capabilities, alongside large‑scale AI upskilling across the workforce. Initiatives such as AI‑native assurance tools and the PwC One platform indicate a push to embed tech-enabled delivery.

Product Line Growth: New and expanded offerings in technology, consulting, strategy, and tax are being built through acquisitions and strategic investments. Within the latest year, Tax and Legal led growth, with Advisory and Assurance also advancing.

Strong Revenue Growth: Revenue rose 23% to $4.92B in FY2026 and increased 22% year over year in Q1 FY2027, marking multiple consecutive years of 20%+ growth. Feedback suggests momentum is sustained across both annual and recent quarterly periods.

Diversified Revenue Streams: Both royalty revenue (+21% in FY2026; +22% in Q1 FY2027) and licensing revenue (+25% in FY2026; +23% in Q1 FY2027) expanded. Feedback suggests growth is coming from both core engines rather than a single category.

Market Expansion: Data‑center royalty revenue more than doubled year over year and Neoverse cores surpassed 1.5B shipments, while initial demand for the AGI CPU exceeded $2B across FY2027–FY2028. Feedback suggests AI data centers and server CPUs are extending the business beyond smartphones.

Strong Revenue Growth: Company-reported figures indicate scale to roughly $80 million in 2024 annual contract value and recognition on the Inc. 5000 list for rapid multi-year expansion. Government contract obligations under a production vehicle and continued awards further reflect meaningful commercial momentum, even as contract ceilings are not revenue.

Profitability: The business is described as having achieved three consecutive profitable years while expanding contract value. This points to growth supported by operating discipline rather than reliance solely on external financing.

Market Expansion: A transition from a DIU prototype to a production-scale agreement and reported deployment across all U.S. military branches and combatant commands indicate widening reach within the defense market. Partnerships and authorizations announced in 2026 are positioned to extend access across combatant commands and federal agencies.

Strong Revenue Growth: Revenue is described as rising at a strong, double‑digit pace across recent quarters and years, with subscription sales increasing alongside total revenue. Company guidance for subscription revenue was raised, reinforcing the momentum.

Resilient & Sustainable Growth: Remaining performance obligations and current contracted revenue expanded, indicating meaningful visibility into future sales. Growth in large enterprise customers and multi‑million‑dollar deals further supports durability.

Innovation-Driven Growth: AI offerings became a meaningful commercial driver as ServiceNow AI exceeded $1 billion in annual contract value and deployments accelerated. Adoption of workflow and AI products is highlighted as a primary catalyst.

Strong Hiring & Retention: Headcount and hiring momentum are evident, with third-party estimates showing growth from roughly the mid‑teens of thousands in 2024 to 20,000+ by 2025–2026 and plans to hire thousands, alongside new capacity such as the Hyderabad operations center. This suggests the company is scaling delivery and talent depth across geographies.

Innovation-Driven Growth: The firm has expanded into AI and digital offerings, including its ZAIDYN platform, acquisitions like Digital Additive and Torrent Consulting, and launches such as Myelo developed with the International Myeloma Foundation. These moves indicate investment beyond traditional consulting into scalable, tech‑enabled services.

Market Expansion: A dedicated mid‑cap pharmaceutical vertical and the opening of an operations center in Hyderabad point to deliberate expansion in target segments and delivery footprint. These steps signal efforts to broaden served markets and strengthen execution capacity.

Product Line Growth: Newer and acquired medicines grew 18% operationally in Q2 2026, while revenue excluding Comirnaty and Paxlovid rose 5% operationally in the same period. Excluding COVID products, 2025 revenue also increased 6% operationally, supported by growth in products such as Eliquis and Padcev.

Cost & Operational Efficiency: Management is pursuing additional savings to improve operational efficiency and support profitability. These cost-control efforts are intended to help the business transition away from pandemic-driven sales while supporting margins.

Innovation-Driven Growth: Investment in future growth includes $10.4 billion in internal R&D during 2025 and ongoing development in oncology and obesity. A broad pipeline and recent acquisitions are intended to offset declining COVID-19 sales and patent expirations if programs succeed.

Profitability: Operating earnings and margins improved notably in 2026, with Q3 operating earnings up sharply year over year and the operating margin rising to 5.6%. Feedback suggests earnings resilience is being supported by operational changes and a shifting business mix.

Strong Revenue Growth: Reported annual revenue expanded from $226.6B in 2023 to $270.6B in 2025, including roughly 12% growth in 2024 and 7% in 2025. This establishes a robust multi‑year revenue trajectory even as recent growth rates have moderated.

Cost & Operational Efficiency: Cost controls and operational improvements are described as lifting earnings despite lower revenue in 2026. Optum Health’s operating earnings rose from $41M to $735M year over year while serving fewer value‑based patients, indicating stronger execution.

Strong Revenue Growth: Company updates describe orders and revenue doubling year over year in FY2026, with independent estimates showing substantial growth through 2024. Additional reporting notes a projection of more than 80% revenue growth for 2026.

Investor Backing & Capital Strength: A $2 billion financing package in March 2026 at a $12.7 billion post-money valuation is cited, including a large Series G and preferred equity. The capital was linked to expansion initiatives and the planned acquisition of Aechelon Technology.

Market Expansion: New defense wins and international deployments are described, including a U.S. Air Force production contract, Coast Guard and Navy programs, and activity across Europe and the Asia-Pacific. Company communications also highlight wider adoption of Hivemind and expansion of V-BAT operations.

Strong Market Position & Advantage: Independent industry tracking places Oura as the dominant smart‑ring vendor, maintaining leadership even as new entrants scale. Shipment growth for the category accelerated while Oura remained the leader.

Strong Revenue Growth: Company and third‑party reports indicate revenue roughly doubled in 2024 with guidance to surpass prior levels in 2025, alongside a sharp acceleration in unit sales. Recent disclosures cite more than half of cumulative sales occurring in the prior year.

Investor Backing & Capital Strength: Late‑2025 fundraising at a significantly higher valuation and substantial capital raised point to strong investor confidence. Added partnerships and ecosystem integrations, including glucose insights collaborations, reinforce access to resources.